LobbyingBlood Cancer United lobbying by quarter
Blood Cancer United's latest lobbying report covers Q2 2026, at $590K. The four quarters Q4 2025–Q3 2026 total $1.3M. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Health Issues.
Blood Cancer United
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $1.3M
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $140K | 1 |
| Q1 2023 | $130K | 1 |
| Q2 2023 | $480K | 1 |
| Q3 2023 | $150K | 1 |
| Q4 2023 | $440K | 1 |
| Q1 2024 | $100K | 1 |
| Q2 2024 | $570K | 1 |
| Q3 2024 | $160K | 1 |
| Q4 2024 | $180K | 1 |
| Q1 2025 | $130K | 1 |
| Q2 2025 | $1.1M | 1 |
| Q3 2025 | $140K | 1 |
| Q4 2025 | $610K | 1 |
| Q1 2026 | $110K | 1 |
| Q2 2026 | $590K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Budget and appropriations$1.2M · 15 reports
- Health issues$1.2M · 15 reports
- Medicare and Medicaid$1.2M · 15 reports
- Medical research and clinical labs$966K · 12 reports
- Taxation$301K · 4 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Health & Human Services, Dept of (HHS)11 reports
- Centers For Medicare and Medicaid Services (CMS)10 reports
- Natl Institutes of Health (NIH)10 reports
- White House Office9 reports
- Food & Drug Administration (FDA)7 reports
- Treasury, Dept of5 reports
- Labor, Dept of (DOL)4 reports
- Office of Management & Budget (OMB)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseBlood Cancer United | $5M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $590K |
| 04/20for Q1 | In-house | $110K |
| 01/20for Q4 2025 | In-house | $610K |
| 25/10/23for Q3 2025 | In-house | $140K |
| 25/07/21for Q2 2025 | In-house | $1.1M |
| 25/04/22for Q1 2025 | In-house | $130K |
| 25/02/03for Q4 2024 | In-house | $180K |
| 24/10/21for Q3 2024 | In-house | $160K |
| 24/07/22for Q2 2024 | In-house | $570K |
| 24/04/30for Q1 2024 | In-house | $100K |
| 24/02/05for Q4 2023 | In-house | $440K |
| 23/10/23for Q3 2023 | In-house | $150K |
| 23/07/20for Q2 2023 | In-house | $480K |
| 23/04/14for Q1 2023 | In-house | $130K |
| 23/01/20for Q4 2022 | In-house | $140K |